Experimental models of hepatocellular carcinoma

Journal of Hepatology

Volumn 48, Issue 5, 2008, Pages 858-879

  Newell, Philippa ^a   Villanueva, Augusto ^a   Friedman, Scott L ^a   Koike, Kazuhiko ^b   Llovet, Josep M ^a,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b KYOTO UNIVERSITY   (Japan)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Cirrhosis; Genetically engineered mice; Hepatocellular carcinoma; Liver cancer; Mouse models

Indexed keywords

BETA CATENIN; CARBON TETRACHLORIDE; CARCINOGEN; CIPROFIBRATE; DIETHYLNITROSAMINE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; N (2 FLUORENYL)ACETAMIDE; PHENOBARBITAL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; RETINOBLASTOMA PROTEIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SOMATOMEDIN; TETRACYCLINE; THIOACETAMIDE; TRANSCRIPTION FACTOR E2F; UROKINASE; VIRUS T ANTIGEN; WNT PROTEIN;

CANCER RESEARCH; COMPARATIVE STUDY; EXPERIMENTAL ANIMAL; FUNCTIONAL GENOMICS; GENE EXPRESSION; GENE TARGETING; GENETIC HETEROGENEITY; HEPATITIS C VIRUS; HEPATITIS VIRUS; HUMAN; KNOCKOUT MOUSE; LIVER CELL CARCINOMA; LIVER FIBROSIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; SCID MOUSE; SIMIAN VIRUS 40; TELOMERE; TRANSGENIC MOUSE; TRANSGENIC ORGANISM; XENOGRAFT;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CELL CYCLE; DISEASE MODELS, ANIMAL; GENOMICS; HEPATITIS B; HEPATITIS C; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; NEOPLASM TRANSPLANTATION; TELOMERE; TRANSPLANTATION, HETEROLOGOUS;

EID: 41249102034     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.01.008     Document Type: Review

References (199)

1. El-Serag H.B., and Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132 (2007) 2557-2576
2. Farazi P.A., and DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6 (2006) 674-687
3. Chiang D. Focal VEGFA gains and molecular classification of hepatocellular carcinomas. Hepatology 46 (2007) 530A
4. Frese K.K., and Tuveson D.A. Maximizing mouse cancer models. Nat Rev Cancer 7 (2007) 654-658
5. Rygaard J., and Povlsen C.O. Heterotransplantation of a human malignant tumour to "Nude" mice. Acta Pathol Microbiol Scand 77 (1969) 758-760
6. Kelland L.R. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 40 (2004) 827-836
7. Venditti J.M. Preclinical drug development: rationale and methods. Semin Oncol 8 (1981) 349-361
8. Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48 (1988) 589-601
9. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83 (1991) 757-766
10. Johnson J.I., Decker S., Zaharevitz D., Rubinstein L.V., Venditti J.M., Schepartz S., et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84 (2001) 1424-1431
11. Voskoglou-Nomikos T., Pater J.L., and Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 9 (2003) 4227-4239
12. Kerbel R.S. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther 2 (2003) S134-S139
13. Inaba M., Kobayashi T., Tashiro T., and Sakurai Y. Pharmacokinetic approach to rational therapeutic doses for human tumor-bearing nude mice. Jpn J Cancer Res 79 (1988) 509-516
14. De Both N.J., Vermey M., Groen N., Dinjens W.N., and Bosman F.T. Clonal growth of colorectal-carcinoma cell lines transplanted to nude mice. Int J Cancer 72 (1997) 1137-1141
15. Staroselsky A.N., Radinsky R., Fidler I.J., Pathak S., Chernajovsky Y., and Frost P. The use of molecular genetic markers to demonstrate the effect of organ environment on clonal dominance in a human renal-cell carcinoma grown in nude mice. Int J Cancer 51 (1992) 130-138
16. Hoffman R.M. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. Methods Mol Med 111 (2005) 297-322
17. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449 (2007) 557-563
18. Wu C., Wei Q., Utomo V., Nadesan P., Whetstone H., Kandel R., et al. Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res 67 (2007) 8216-8222
19. Tuveson D.A., and Jacks T. Technologically advanced cancer modeling in mice. Curr Opin Genet Dev 12 (2002) 105-110
20. Rangarajan A., and Weinberg R.A. Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer 3 (2003) 952-959
21. Blasco M.A., Lee H.W., Hande M.P., Samper E., Lansdorp P.M., DePinho R.A., et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91 (1997) 25-34
22. Maddison K., and Clarke A.R. New approaches for modelling cancer mechanisms in the mouse. J Pathol 205 (2005) 181-193
23. Jaenisch R. Transgenic animals. Science 240 (1988) 1468-1474
24. Macleod K.F., and Jacks T. Insights into cancer from transgenic mouse models. J Pathol 187 (1999) 43-60
25. Jacks T., Fazeli A., Schmitt E.M., Bronson R.T., Goodell M.A., and Weinberg R.A. Effects of an Rb mutation in the mouse. Nature 359 (1992) 295-300
26. Robanus-Maandag E., Dekker M., van der Valk M., Carrozza M.L., Jeanny J.C., Dannenberg J.H., et al. p107 is a suppressor of retinoblastoma development in pRb-deficient mice. Genes Dev 12 (1998) 1599-1609
27. Adams J.M., Harris A.W., Pinkert C.A., Corcoran L.M., Alexander W.S., Cory S., et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318 (1985) 533-538
28. Gannon M., Gamer L.W., and Wright C.V. Regulatory regions driving developmental and tissue-specific expression of the essential pancreatic gene pdx1. Dev Biol 238 (2001) 185-201
29. Mattick J.S., and Makunin I.V. Non-coding RNA. Hum Mol Genet 15 (2006) R17-R29
30. Palmiter R.D., and Brinster R.L. Germ-line transformation of mice. Annu Rev Genet 20 (1986) 465-499
31. Dorer D.R. Do transgene arrays form heterochromatin in vertebrates?. Transgenic Res 6 (1997) 3-10
32. Politi K., Kljuic A., Szabolcs M., Fisher P., Ludwig T., and Efstratiadis A. 'Designer' tumors in mice. Oncogene 23 (2004) 1558-1565
33. Jonkers J., and Berns A. Conditional mouse models of sporadic cancer. Nat Rev Cancer 2 (2002) 251-265
34. Baron U., and Bujard H. Tet repressor-based system for regulated gene expression in eukaryotic cells: principles and advances. Methods Enzymol 327 (2000) 401-421
35. Gossen M., Freundlieb S., Bender G., Muller G., Hillen W., and Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 268 (1995) 1766-1769
36. Le Y., and Sauer B. Conditional gene knockout using Cre recombinase. Mol Biotechnol 17 (2001) 269-275
37. Branda C.S., and Dymecki S.M. Talking about a revolution: The impact of site-specific recombinases on genetic analyses in mice. Dev Cell 6 (2004) 7-28
38. Sadowski P.D. The Flp recombinase of the 2-microns plasmid of Saccharomyces cerevisiae. Prog Nucleic Acid Res Mol Biol 51 (1995) 53-91
39. Lakso M., Sauer B., Mosinger Jr. B., Lee E.J., Manning R.W., Yu S.H., et al. Targeted oncogene activation by site-specific recombination in transgenic mice. Proc Natl Acad Sci USA 89 (1992) 6232-6236
40. Feo F., De Miglio M.R., Simile M.M., Muroni M.R., Calvisi D.F., Frau M., et al. Hepatocellular carcinoma as a complex polygenic disease. Interpretive analysis of recent developments on genetic predisposition. Biochim Biophys Acta 1765 (2006) 126-147
41. Feo F., Pascale R., and Calvisi D. Models for liver cancer. In: Alison M. (Ed). The cancer handbook. 2nd ed. (2007), John Wiley & Sons 1-16
42. Huynh H., Soo K.C., Chow P.K., Panasci L., and Tran E. Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin Cancer Res 12 (2006) 4306-4314
43. Ma S., Chan K.W., Hu L., Lee T.K., Wo J.Y., Ng I.O., et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132 (2007) 2542-2556
44. Ma S., Lee T.K., Zheng B.J., Chan K.W., and Guan X.Y. CD133(+) HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27 (2008) 1749-1758
45. Kornek M., Raskopf E., Tolba R., Becker U., Klockner M., Sauerbruch T., et al. Accelerated orthotopic HCC growth is linked to increased expression of pro-angiogenic and pro-metastatic factors in murine liver fibrosis. Liver Int 28 (2008) 509-518
46. Rustgi V.K. The epidemiology of hepatitis C infection in the United States. J Gastroenterol 42 (2007) 513-521
47. Chisari F.V., Klopchin K., Moriyama T., Pasquinelli C., Dunsford H.A., Sell S., et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 59 (1989) 1145-1156
48. Koike K., Moriya K., Iino S., Yotsuyanagi H., Endo Y., Miyamura T., et al. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology 19 (1994) 810-819
49. Yu D.Y., Moon H.B., Son J.K., Jeong S., Yu S.L., Yoon H., et al. Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein. J Hepatol 31 (1999) 123-132
50. Slagle B.L., Lee T.H., Medina D., Finegold M.J., and Butel J.S. Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene. Mol Carcinog 15 (1996) 261-269
51. Koike K. Transgenic mouse models of viral hepatitis: insight into viral hepatocarcinogenesis. Viral Hepatitis Rev 5 (1999) 177-203
52. Chisari F.V., Filippi P., Buras J., McLachlan A., Popper H., Pinkert C.A., et al. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice. Proc Natl Acad Sci USA 84 (1987) 6909-6913
53. Dunsford H.A., Sell S., and Chisari F.V. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. Cancer Res 50 (1990) 3400-3407
54. Liang T.J., and Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 127 (2004) S62-S71
55. Kawamura T., Furusaka A., Koziel M.J., Chung R.T., Wang T.C., Schmidt E.V., et al. Transgenic expression of hepatitis C virus structural proteins in the mouse. Hepatology 25 (1997) 1014-1021
56. Kamegaya Y., Hiasa Y., Zukerberg L., Fowler N., Blackard J.T., Lin W., et al. Hepatitis C virus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis. Hepatology 41 (2005) 660-667
57. Moriya K., Yotsuyanagi H., Shintani Y., Fujie H., Ishibashi K., Matsuura Y., et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 78 (1997) 1527-1531
58. Moriya K., Fujie H., Shintani Y., Yotsuyanagi H., Tsutsumi T., Ishibashi K., et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4 (1998) 1065-1067
59. Koike K., Moriya K., and Kimura S. Role of hepatitis C virus in the development of hepatocellular carcinoma: transgenic approach to viral hepatocarcinogenesis. J Gastroenterol Hepatol 17 (2002) 394-400
60. Lerat H., Honda M., Beard M.R., Loesch K., Sun J., Yang Y., et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 122 (2002) 352-365
61. Moriya K., Todoroki T., Tsutsumi T., Fujie H., Shintani Y., Miyoshi H., et al. Increase in the concentration of carbon 18 monounsaturated fatty acids in the liver with hepatitis C: analysis in transgenic mice and humans. Biochem Biophys Res Commun 281 (2001) 1207-1212
62. Moriya K., Nakagawa K., Santa T., Shintani Y., Fujie H., Miyoshi H., et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 61 (2001) 4365-4370
63. Radaeva S., Li Y., Hacker H.J., Burger V., Kopp-Schneider A., and Bannasch P. Hepadnaviral hepatocarcinogenesis: in situ visualization of viral antigens, cytoplasmic compartmentation, enzymic patterns, and cellular proliferation in preneoplastic hepatocellular lineages in woodchucks. J Hepatol 33 (2000) 580-600
64. Tennant B.C., Toshkov I.A., Peek S.F., Jacob J.R., Menne S., Hornbuckle W.E., et al. Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection. Gastroenterology 127 (2004) S283-S293
65. Yang D., Alt E., and Rogler C.E. Coordinate expression of N-myc 2 and insulin-like growth factor II in precancerous altered hepatic foci in woodchuck hepatitis virus carriers. Cancer Res 53 (1993) 2020-2027
66. Farazi P.A., Glickman J., Horner J., and Depinho R.A. Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression. Cancer Res 66 (2006) 4766-4773
67. Lewis B.C., Klimstra D.S., Socci N.D., Xu S., Koutcher J.A., and Varmus H.E. The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma. Mol Cell Biol 25 (2005) 1228-1237
68. Chen Y.W., Klimstra D.S., Mongeau M.E., Tatem J.L., Boyartchuk V., and Lewis B.C. Loss of p53 and Ink4a/Arf cooperate in a cell autonomous fashion to induce metastasis of hepatocellular carcinoma cells. Cancer Res 67 (2007) 7589-7596
69. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445 (2007) 656-660
70. Yamasaki L. Balancing proliferation and apoptosis in vivo: the Goldilocks theory of E2F/DP action. Biochim Biophys Acta 1423 (1999) M9-M15
71. Conner E.A., Lemmer E.R., Omori M., Wirth P.J., Factor V.M., and Thorgeirsson S.S. Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis. Oncogene 19 (2000) 5054-5062
72. Calvisi D.F., Conner E.A., Ladu S., Lemmer E.R., Factor V.M., and Thorgeirsson S.S. Activation of the canonical Wnt/beta-catenin pathway confers growth advantages in c-myc/E2F1 transgenic mouse model of liver cancer. J Hepatol 42 (2005) 842-849
73. Ali S.H., and DeCaprio J.A. Cellular transformation by SV40 large T antigen: interaction with host proteins. Semin Cancer Biol 11 (2001) 15-23
74. Sandgren E.P., Quaife C.J., Pinkert C.A., Palmiter R.D., and Brinster R.L. Oncogene-induced liver neoplasia in transgenic mice. Oncogene 4 (1989) 715-724
75. Manickan E., Satoi J., Wang T.C., and Liang T.J. Conditional liver-specific expression of simian virus 40 T antigen leads to regulatable development of hepatic neoplasm in transgenic mice. J Biol Chem 276 (2001) 13989-13994
76. Hayflick L., and Moorhead P.S. The serial cultivation of human diploid cell strains. Exp Cell Res 25 (1961) 585-621
77. Artandi S.E., and DePinho R.A. Mice without telomerase: what can they teach us about human cancer?. Nat Med 6 (2000) 852-855
78. Hastie N.D., Dempster M., Dunlop M.G., Thompson A.M., Green D.K., and Allshire R.C. Telomere reduction in human colorectal carcinoma and with ageing. Nature 346 (1990) 866-868
79. Llovet J.M., Chen Y., Wurmbach E., Roayaie S., Fiel M.I., Schwartz M., et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 131 (2006) 1758-1767
80. Satra M., Gatselis N., Iliopoulos D., Zacharoulis D., Dalekos G.N., and Tsezou A. Real-time quantification of human telomerase reverse transcriptase mRNA in liver tissues from patients with hepatocellular cancer and chronic viral hepatitis. J Viral Hepat 14 (2007) 41-47
81. Miura N., Horikawa I., Nishimoto A., Ohmura H., Ito H., Hirohashi S., et al. Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis. Cancer Genet Cytogenet 93 (1997) 56-62
82. Wiemann S.U., Satyanarayana A., Tsahuridu M., Tillmann H.L., Zender L., Klempnauer J., et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. Faseb J 16 (2002) 935-942
83. Plentz R.R., Caselitz M., Bleck J.S., Gebel M., Flemming P., Kubicka S., et al. Hepatocellular telomere shortening correlates with chromosomal instability and the development of human hepatoma. Hepatology 40 (2004) 80-86
84. Kipling D., and Cooke H.J. Hypervariable ultra-long telomeres in mice. Nature 347 (1990) 400-402
85. Artandi S.E., Chang S., Lee S.L., Alson S., Gottlieb G.J., Chin L., et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 406 (2000) 641-645
86. Jhappan C., Stahle C., Harkins R.N., Fausto N., Smith G.H., and Merlino G.T. TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 61 (1990) 1137-1146
87. Lee G.H., Merlino G., and Fausto N. Development of liver tumors in transforming growth factor alpha transgenic mice. Cancer Res 52 (1992) 5162-5170
88. Sandgren E.P., Luetteke N.C., Palmiter R.D., Brinster R.L., and Lee D.C. Overexpression of TGF alpha in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61 (1990) 1121-1135
89. Schiffer E., Housset C., Cacheux W., Wendum D., Desbois-Mouthon C., Rey C., et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 41 (2005) 307-314
90. Lee J.S., Chu I.S., Mikaelyan A., Calvisi D.F., Heo J., Reddy J.K., et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genet 36 (2004) 1306-1311
91. Wang R., Ferrell L.D., Faouzi S., Maher J.J., and Bishop J.M. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol 153 (2001) 1023-1034
92. Zender L., Spector M.S., Xue W., Flemming P., Cordon-Cardo C., Silke J., et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125 (2006) 1253-1267
93. Park W.S., Dong S.M., Kim S.Y., Na E.Y., Shin M.S., Pi J.H., et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 59 (1999) 307-310
94. Takami T., Kaposi-Novak P., Uchida K., Gomez-Quiroz L.E., Conner E.A., Factor V.M., et al. Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res 67 (2007) 9844-9851
95. Sakata H., Takayama H., Sharp R., Rubin J.S., Merlino G., and LaRochelle W.J. Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. Cell Growth Differ 7 (1996) 1513-1523
96. Apte U., Zeng G., Muller P., Tan X., Micsenyi A., Cieply B., et al. Activation of Wnt/beta-catenin pathway during hepatocyte growth factor-induced hepatomegaly in mice. Hepatology 44 (2006) 992-1002
97. Santoni-Rugiu E., Preisegger K.H., Kiss A., Audolfsson T., Shiota G., Schmidt E.V., et al. Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model. Proc Natl Acad Sci USA 93 (1996) 9577-9582
98. Shiota G., Kawasaki H., Nakamura T., and Schmidt E.V. Characterization of double transgenic mice expressing hepatocye growth factor and transforming growth factor alpha. Res Commun Mol Pathol Pharmacol 90 (1995) 17-24
99. Tward A.D., Jones K.D., Yant S., Cheung S.T., Fan S.T., Chen X., et al. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci USA 104 (2007) 14771-14776
100. Bellacosa A., Testa J.R., Staal S.P., and Tsichlis P.N. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 254 (1991) 274-277
101. Staal S.P., Hartley J.W., and Rowe W.P. Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. Proc Natl Acad Sci USA 74 (1977) 3065-3067
102. Bellacosa A., de Feo D., Godwin A.K., Bell D.W., Cheng J.Q., Altomare D.A., et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64 (1995) 280-285
103. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2 (2002) 489-501
104. Stanger B.Z., Stiles B., Lauwers G.Y., Bardeesy N., Mendoza M., Wang Y., et al. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 8 (2005) 185-195
105. Bernal-Mizrachi E., Wen W., Stahlhut S., Welling C.M., and Permutt M.A. Islet beta cell expression of constitutively active Akt1/PKB alpha induces striking hypertrophy, hyperplasia, and hyperinsulinemia. J Clin Invest 108 (2001) 1631-1638
106. Shioi T., McMullen J.R., Kang P.M., Douglas P.S., Obata T., Franke T.F., et al. Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol 22 (2002) 2799-2809
107. Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10 (2004) 594-601
108. Horie Y., Suzuki A., Kataoka E., Sasaki T., Hamada K., Sasaki J., et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 113 (2004) 1774-1783
109. Watanabe S., Horie Y., Kataoka E., Sato W., Dohmen T., Ohshima S., et al. Non-alcoholic steatohepatitis and hepatocellular carcinoma: lessons from hepatocyte-specific phosphatase and tensin homolog (PTEN)-deficient mice. J Gastroenterol Hepatol 22 (2007) S96-S100
110. Breuhahn K., Longerich T., and Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 25 (2006) 3787-3800
111. Braulke T. Type-2 IGF receptor: a multi-ligand binding protein. Horm Metab Res 31 (1999) 242-246
112. Iizuka N., Oka M., Yamada-Okabe H., Mori N., Tamesa T., Okada T., et al. Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res 62 (2002) 3939-3944
113. Schirmacher P., Held W.A., Yang D., Chisari F.V., Rustum Y., and Rogler C.E. Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth. Cancer Res 52 (1992) 2549-2556
114. Yamaguchi K., Carr B.I., and Nalesnik M.A. Concomitant and isolated expression of TGF-alpha and EGF-R in human hepatoma cells supports the hypothesis of autocrine, paracrine, and endocrine growth of human hepatoma. J Surg Oncol 58 (1995) 240-245
115. Tonjes R.R., Lohler J., O'Sullivan J.F., Kay G.F., Schmidt G.H., Dalemans W., et al. Autocrine mitogen IgEGF cooperates with c-myc or with the Hcs locus during hepatocarcinogenesis in transgenic mice. Oncogene 10 (1995) 765-768
116. Tan X., Behari J., Cieply B., Michalopoulos G.K., and Monga S.P. Conditional deletion of beta-catenin reveals its role in liver growth and regeneration. Gastroenterology 131 (2006) 1561-1572
117. McLin V.A., and Zorn A.M. Molecular control of liver development. Clin Liver Dis 10 (2006) 1-25
118. Thorgeirsson S.S., and Grisham J.W. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31 (2002) 339-346
119. Satoh S., Daigo Y., Furukawa Y., Kato T., Miwa N., Nishiwaki T., et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 24 (2000) 245-250
120. Miyoshi Y., Iwao K., Nagasawa Y., Aihara T., Sasaki Y., Imaoka S., et al. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 58 (1998) 2524-2527
121. de La Coste A., Romagnolo B., Billuart P., Renard C.A., Buendia M.A., Soubrane O., et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 95 (1998) 8847-8851
122. Taniguchi K., Roberts L.R., Aderca I.N., Dong X., Qian C., Murphy L.M., et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 21 (2002) 4863-4871
123. Laurent-Puig P., Legoix P., Bluteau O., Belghiti J., Franco D., Binot F., et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 120 (2001) 1763-1773
124. Wong C.M., Fan S.T., and Ng I.O. beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 92 (2001) 136-145
125. Wei Y., Van Nhieu J.T., Prigent S., Srivatanakul P., Tiollais P., and Buendia M.A. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, beta-catenin expression, and clinical features. Hepatology 36 (2002) 692-701
126. Fukutomi T., Zhou Y., Kawai S., Eguchi H., Wands J.R., and Li J. Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of wnt-1 expression. Hepatology 41 (2005) 1096-1105
127. Cadoret A., Ovejero C., Saadi-Kheddouci S., Souil E., Fabre M., Romagnolo B., et al. Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin. Cancer Res 61 (2001) 3245-3249
128. Harada N., Miyoshi H., Murai N., Oshima H., Tamai Y., Oshima M., et al. Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin. Cancer Res 62 (2002) 1971-1977
129. Tan X., Apte U., Micsenyi A., Kotsagrelos E., Luo J.H., Ranganathan S., et al. Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver. Gastroenterology 129 (2005) 285-302
130. Colnot S., Decaens T., Niwa-Kawakita M., Godard C., Hamard G., Kahn A., et al. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci USA 101 (2004) 17216-17221
131. Harada N., Oshima H., Katoh M., Tamai Y., Oshima M., and Taketo M.M. Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. Cancer Res 64 (2004) 48-54
132. Nicholes K., Guillet S., Tomlinson E., Hillan K., Wright B., Frantz G.D., et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 160 (2002) 2295-2307
133. Sandgren E.P., Palmiter R.D., Heckel J.L., Brinster R.L., and Degen J.L. DNA rearrangement causes hepatocarcinogenesis in albumin-plasminogen activator transgenic mice. Proc Natl Acad Sci USA 89 (1992) 11523-11527
134. Claria J., and Jimenez W. Experimental models of cirrhosis and ascites. In: Gines P.A.V., Rodes J., and Schrier R.W. (Eds). Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment. 2nd ed. (2005), Blackwell Publishing, Malden, Massachusetts 215-226
135. Solt D.B., Medline A., and Farber E. Rapid emergence of carcinogen-induced hyperplastic lesions in a new model for the sequential analysis of liver carcinogenesis. Am J Pathol 88 (1977) 595-618
136. Farber E., and Sarma D.S. Hepatocarcinogenesis: a dynamic cellular perspective. Lab Invest 56 (1987) 4-22
137. Feo F., Pascale R.M., Simile M.M., De Miglio M.R., Muroni M.R., and Calvisi D. Genetic alterations in liver carcinogenesis: implications for new preventive and therapeutic strategies. Crit Rev Oncog 11 (2000) 19-62
138. McCay P.B., Lai E.K., Poyer J.L., DuBose C.M., and Janzen E.G. Oxygen- and carbon-centered free radical formation during carbon tetrachloride metabolism. Observation of lipid radicals in vivo and in vitro. J Biol Chem 259 (1984) 2135-2143
139. Encell L., Foiles P.G., and Gold B. The relationship between N-nitrosodimethylamine metabolism and DNA methylation in isolated rat hepatocytes. Carcinogenesis 17 (1996) 1127-1134
140. Jenkins S.A., Grandison A., Baxter J.N., Day D.W., Taylor I., and Shields R. A dimethylnitrosamine-induced model of cirrhosis and portal hypertension in the rat. J Hepatol 1 (1985) 489-499
141. Goldfarb S., Pugh T.D., Koen H., and He Y.Z. Preneoplastic and neoplastic progression during hepatocarcinogenesis in mice injected with diethylnitrosamine in infancy. Environ Health Perspect 50 (1983) 149-161
142. Koen H., Pugh T.D., and Goldfarb S. Centrilobular distribution of diethylnitrosamine-induced hepatocellular foci in the mouse. Lab Invest 49 (1983) 78-81
143. Pascale R.M., Simile M.M., and Feo F. Genomic abnormalities in hepatocarcinogenesis. Implications for a chemopreventive strategy. Anticancer Res 13 (1993) 1341-1356
144. Tsujiuchi T., Tsutsumi M., Sasaki Y., Takahama M., and Konishi Y. Different frequencies and patterns of beta-catenin mutations in hepatocellular carcinomas induced by N-nitrosodiethylamine and a choline-deficient l-amino acid-defined diet in rats. Cancer Res 59 (1999) 3904-3907
145. Gomez-Angelats M., Teeguarden J.G., Dragan Y.P., and Pitot H.C. Mutational analysis of three tumor suppressor genes in two models of rat hepatocarcinogenesis. Mol Carcinog 25 (1999) 157-163
146. Li X., Benjamin I.S., and Alexander B. Reproducible production of thioacetamide-induced macronodular cirrhosis in the rat with no mortality. J Hepatol 36 (2002) 488-493
147. Kang J.S., Morimura K., Salim E.I., Wanibuchi H., Yamaguchi S., and Fukushima S. Persistence of liver cirrhosis in association with proliferation of nonparenchymal cells and altered location of alpha-smooth muscle actin-positive cells. Toxicol Pathol 33 (2005) 329-335
148. Keppler D.O., Pausch J., and Decker K. Selective uridine triphosphate deficiency induced by d-galactosamine in liver and reversed by pyrimidine nucleotide precursors. Effect on ribonucleic acid synthesis. J Biol Chem 249 (1974) 211-216
149. Ghoshal A.K., Ahluwalia M., and Farber E. The rapid induction of liver cell death in rats fed a choline-deficient methionine-low diet. Am J Pathol 113 (1983) 309-314
150. Rushmore T.H., Ghazarian D.M., Subrahmanyan V., Farber E., and Ghoshal A.K. Probable free radical effects on rat liver nuclei during early hepatocarcinogenesis with a choline-devoid low methionine diet. Cancer Res 47 (1987) 6731-6740
151. Chandar N., and Lombardi B. Liver cell proliferation and incidence of hepatocellular carcinomas in rats fed consecutively a choline-devoid and a choline-supplemented diet. Carcinogenesis 9 (1988) 259-263
152. Bissell D.M., Wang S.S., Jarnagin W.R., and Roll F.J. Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. J Clin Invest 96 (1995) 447-455
153. Sanderson N., Factor V., Nagy P., Kopp J., Kondaiah P., Wakefield L., et al. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 92 (1995) 2572-2576
154. Kanzler S., Lohse A.W., Keil A., Henninger J., Dienes H.P., Schirmacher P., et al. TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol 276 (1999) G1059-G1068
155. Schnur J., Olah J., Szepesi A., Nagy P., and Thorgeirsson S.S. Thioacetamide-induced hepatic fibrosis in transforming growth factor beta-1 transgenic mice. Eur J Gastroenterol Hepatol 16 (2004) 127-133
156. Schnur J., Nagy P., Sebestyen A., Schaff Z., and Thorgeirsson S.S. Chemical hepatocarcinogenesis in transgenic mice overexpressing mature TGF beta-1 in liver. Eur J Cancer 35 (1999) 1842-1845
157. Kitisin K., Ganesan N., Tang Y., Jogunoori W., Volpe E.A., Kim S.S., et al. Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation. Oncogene 26 (2007) 7103-7110
158. Wong L., Yamasaki G., Johnson R.J., and Friedman S.L. Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest 94 (1994) 1563-1569
159. Czochra P., Klopcic B., Meyer E., Herkel J., Garcia-Lazaro J.F., Thieringer F., et al. Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J Hepatol 45 (2006) 419-428
160. Campbell J.S., Hughes S.D., Gilbertson D.G., Palmer T.E., Holdren M.S., Haran A.C., et al. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci USA 102 (2005) 3389-3394
161. Abiru S., Migita K., Maeda Y., Daikoku M., Ito M., Ohata K., et al. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 26 (2006) 39-45
162. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317 (2007) 121-124
163. Wands J. Hepatocellular carcinoma and sex. N Engl J Med 357 (2007) 1974-1976
164. Geller S.A., Nichols W.S., Kim S., Tolmachoff T., Lee S., Dycaico M.J., et al. Hepatocarcinogenesis is the sequel to hepatitis in Z#2 alpha 1-antitrypsin transgenic mice: histopathological and DNA ploidy studies. Hepatology 19 (1994) 389-397
165. Katzenellenbogen M., Pappo O., Barash H., Klopstock N., Mizrahi L., Olam D., et al. Multiple adaptive mechanisms to chronic liver disease revealed at early stages of liver carcinogenesis in the Mdr2-knockout mice. Cancer Res 66 (2006) 4001-4010
166. Mauad T.H., van Nieuwkerk C.M., Dingemans K.P., Smit J.J., Schinkel A.H., Notenboom R.G., et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol 145 (1994) 1237-1245
167. Fan C.Y., Pan J., Usuda N., Yeldandi A.V., Rao M.S., and Reddy J.K. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors
168. Coulouaru C., Gomez-Quiroz L.E., Lee J.S., Kaposi-Novak P., Conner E.A., Goldina T.A., et al. Oncogene-specific gene expression signatures at preneoplastic stages in mice define distinct mechanisms of hepatocarcinogenesis. Hepatology 44 (2006) 1003-1011
169. Guerra C., Schuhmacher A.J., Canamero M., Grippo P.J., Verdaguer L., Perez-Gallego L., et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11 (2007) 291-302
170. Hingorani S.R., Wang L., Multani A.S., Combs C., Deramaudt T.B., Hruban R.H., et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7 (2005) 469-483
171. Santoni-Rugiu E., Jensen M.R., and Thorgeirsson S.S. Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha. Cancer Res 58 (1998) 123-134
172. Chien W.M., Garrison K., Caufield E., Orthel J., Dill J., and Fero M.L. Differential gene expression of p27Kip1 and Rb knockout pituitary tumors associated with altered growth and angiogenesis. Cell Cycle 6 (2007) 750-757
173. Wong A.K., and Chin L. An inducible melanoma model implicates a role for RAS in tumor maintenance and angiogenesis. Cancer Metastasis Rev 19 (2000) 121-129
174. Wu X., Wu J., Huang J., Powell W.C., Zhang J., Matusik R.J., et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 101 (2001) 61-69
175. Chisari F.V., Pinkert C.A., Milich D.R., Filippi P., McLachlan A., Palmiter R.D., et al. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science 230 (1985) 1157-1160
176. Toshkov I., Chisari F.V., and Bannasch P. Hepatic preneoplasia in hepatitis B virus transgenic mice. Hepatology 20 (1994) 1162-1172
177. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 4 (1994) 1-7
178. Santoni-Rugiu E., Nagy P., Jensen M.R., Factor V.M., and Thorgeirsson S.S. Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha. Am J Pathol 149 (1996) 407-428
179. Conner E.A., Lemmer E.R., Sanchez A., Factor V.M., and Thorgeirsson S.S. E2F1 blocks and c-myc accelerates hepatic ploidy in transgenic mouse models. Biochem Biophys Res Commun 302 (2003) 114-120
180. Dalemans W., Perraud F., Le Meur M., Gerlinger P., Courtney M., and Pavirani A. Heterologous protein expression by transimmortalized differentiated liver cell lines derived from transgenic mice (hepatomas/alpha 1 antitrypsin/ONC mouse). Biologicals 18 (1990) 191-198
181. Perraud F., Dalemans W., Gendrault J.L., Dreyer D., Ali-Hadji D., Faure T., et al. Characterization of trans-immortalized hepatic cell lines established from transgenic mice. Exp Cell Res 195 (1991) 59-65
182. Murakami H., Sanderson N.D., Nagy P., Marino P.A., Merlino G., and Thorgeirsson S.S. Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res 53 (1993) 1719-1723
183. Schirmacher P., Held W.A., Yang D., Biempica L., and Rogler C.E. Selective amplification of periportal transitional cells precedes formation of hepatocellular carcinoma in SV40 large tag transgenic mice. Am J Pathol 139 (1991) 231-241
184. Messing A., Chen H.Y., Palmiter R.D., and Brinster R.L. Peripheral neuropathies, hepatocellular carcinomas and islet cell adenomas in transgenic mice. Nature 316 (1985) 461-463
185. Sepulveda A.R., Finegold M.J., Smith B., Slagle B.L., DeMayo J.L., Shen R.F., et al. Development of a transgenic mouse system for the analysis of stages in liver carcinogenesis using tissue-specific expression of SV40 large T-antigen controlled by regulatory elements of the human alpha-1-antitrypsin gene. Cancer Res 49 (1989) 6108-6117
186. Dubois N., Bennoun M., Allemand I., Molina T., Grimber G., Daudet-Monsac M., et al. Time-course development of differentiated hepatocarcinoma and lung metastasis in transgenic mice. J Hepatol 13 (1991) 227-239
187. Rogler C.E., Yang D., Rossetti L., Donohoe J., Alt E., Chang C.J., et al. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem 269 (1994) 13779-13784
188. Harris T.M., Rogler L.E., and Rogler C.E. Reactivation of the maternally imprinted IGF2 allele in TGFalpha induced hepatocellular carcinomas in mice. Oncogene 16 (1998) 203-209
189. Shiota G., Wang T.C., Nakamura T., and Schmidt E.V. Hepatocyte growth factor in transgenic mice: effects on hepatocyte growth, liver regeneration and gene expression. Hepatology 19 (1994) 962-972
190. Yaswen P., Goyette M., Shank P.R., and Fausto N. Expression of c-Ki-ras, c-Ha-ras, and c-myc in specific cell types during hepatocarcinogenesis. Mol Cell Biol 5 (1985) 780-786
191. Chandar N., Lombardi B., and Locker J. c-myc gene amplification during hepatocarcinogenesis by a choline-devoid diet. Proc Natl Acad Sci USA 86 (1989) 2703-2707
192. Nagy P., Evarts R.P., Marsden E., Roach J., and Thorgeirsson S.S. Cellular distribution of c-myc transcripts during chemical hepatocarcinogenesis in rats. Cancer Res 48 (1988) 5522-5527
193. Rao M.S., Lalwani N.D., Watanabe T.K., and Reddy J.K. Inhibitory effect of antioxidants ethoxyquin and 2(3)-tert-butyl-4-hydroxyanisole on hepatic tumorigenesis in rats fed ciprofibrate, a peroxisome proliferator. Cancer Res 44 (1984) 1072-1076
194. Groos J., Bannasch P., Schwarz M., and Kopp-Schneider A. Comparison of mode of action of four hepatocarcinogens: a model-based approach. Toxicol Sci 99 (2007) 446-454
195. Poirier L.A. Hepatocarcinogenesis by diethylnitrosamine in rats fed high dietary levels of lipotropes. J Natl Cancer Inst 54 (1975) 137-140
196. Williams G.M., Iatropoulos M.J., Wang C.X., Jeffrey A.M., Thompson S., Pittman B., et al. Nonlinearities in 2-acetylaminofluorene exposure responses for genotoxic and epigenetic effects leading to initiation of carcinogenesis in rat liver. Toxicol Sci 45 (1998) 152-161
197. Calvisi D.F., Ladu S., Factor V.M., and Thorgeirsson S.S. Activation of beta-catenin provides proliferative and invasive advantages in c-myc/TGF-alpha hepatocarcinogenesis promoted by phenobarbital. Carcinogenesis 25 (2004) 901-908
198. Lee G.H. Paradoxical effects of phenobarbital on mouse hepatocarcinogenesis. Toxicol Pathol 28 (2000) 215-225
199. Tang Y., Katuri V., Dillner A., Mishra B., Deng C.X., and Mishra L. Disruption of transforming growth factor-beta signaling in ELF beta-spectrin-deficient mice. Science 299 (2003) 574-577